Full Schedule

17:00 - 18:30 GMT

Pfizer Young Investigators Session

Location: Lenox 2

Speaker: – Pfizer

Networking

17:01 - 17:05 GMT

YI - Sponsor Address

Location: Lenox 2

Speaker: – Pfizer

17:05 - 17:10 GMT

YI - Session and Speaker Intro

Location: Lenox 2

Chair: – Medical Oncology Department. Hospital Universitario Marques de Valdecilla

17:10 - 17:19 GMT

YI - Academic Opportunities

Location: Lenox 2

Speaker: – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

17:19 - 17:28 GMT

YI - Industry Opportunities

Location: Lenox 2

Panelist:

17:28 - 17:37 GMT

YI- FDA and Regulatory Opportunities

Location: Lenox 2

Speaker: – University of Texas MD Anderson Cancer Center

17:37 - 17:46 GMT

YI- Private-practice Opportunities

Location: Lenox 2

17:46 - 17:55 GMT

YI- Basic Science Opportunities

Location: Lenox 2

Speaker: – Charité - University Hospital

17:55 - 18:04 GMT

YI - Long- Term Industry Opportunities/ Experiences

Location: Lenox 2

Speaker: – Pfizer

18:04 - 18:27 GMT

YI - Panel Discussion

Location: Lenox 2

Panelist: – Pfizer

18:27 - 18:30 GMT

YI- Session Wrap Up

Location: Lenox 2

Chair: – Medical Oncology Department. Hospital Universitario Marques de Valdecilla

08:30 - 10:00 GMT

WELCOME SESSION AND SESSION 1: Challenges in Surgical Decision Making

Location: Lenox 3

Moderator: – University of Southern Denmark

Moderator: – Mayo Clinic

CME Session

CME Credits: 1.5 CE credits

08:31 - 08:35 GMT

Welcome Address Speaker

Location: Lenox 3

Speaker: – Mayo Clinic

08:35 - 08:45 GMT

Treatment Options for Clinical TI A Renal Masses A: Introduction of Active Surveillance vs. Therapy

Location: Lenox 3

Speaker: – University of Washington

08:46 - 08:57 GMT

B: Surgical options for localized disease

Location: Lenox 3

Speaker: – Dep of Urology, university Hospital Örebro

08:57 - 09:08 GMT

C: Ablation Techniques for localized RCC

Location: Lenox 3

Speaker:

09:08 - 09:19 GMT

Neoadjuvant Therapy-An Update

Location: Lenox 3

Speaker: – University of Cambridge

09:19 - 09:30 GMT

Risk of Recurrence, Classification Systems and Pathological Background

Location: Lenox 3

*Speaker: – The Netherlands Cancer Institute

09:30 - 09:41 GMT

Results from Adjuvant Trials: how to select patients and therapies

Location: Lenox 3

Speaker: – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany

09:41 - 09:52 GMT

Cytoreductive Nephrectomy in Metastatic Disease: who, how, when?

Location: Lenox 3

Speaker: – HEGP, APHP, Université Paris-Centre

09:52 - 10:00 GMT

Session 1 Q&A

Location: Lenox 3

Moderator: – University of Southern Denmark

Moderator: – Mayo Clinic

10:05 - 10:15 GMT

BREAK

Location: Lenox 1

10:15 - 11:30 GMT

SESSION 2: Understanding Renal Cell Carcinoma

Location: Lenox 3

Moderator: – The Francis Crick Institute/ The Royal Marsden Hospital

Moderator: – Brigham and Women's Hospital, Harvard Medical School

CME Session

CME Credits: 1.25 CE credits

10:16 - 10:17 GMT

Introduction to Session 2

Location: Lenox 3

Speaker: – The Francis Crick Institute/ The Royal Marsden Hospital

10:17 - 10:27 GMT

WHO pathological classification: Present and Future

Location: Lenox 3

Speaker: – Fundacio Puigvert. Universitat Autònoma de Barcelona-Spain

10:27 - 10:37 GMT

Artificial Intelligence and Digital Pathology- New tools in RCC for Diagnosis and Precision Oncology

Location: Lenox 3

Speaker: – University of Texas Southwestern

10:37 - 10:47 GMT

Phase II study of nivolumab and salvage nivolumab + ipilimumab in RCC (HCRN GU16-260): Correlative Results

Speaker: – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

10:47 - 10:57 GMT

Epigenetic regulation by PBRM1 in ccRCC

Location: Lenox 3

Speaker: – The Institute of Cancer Research

10:57 - 11:07 GMT

Non-Clear Cell RCC: From Chromophobe to Translocation and Beyond

Location: Lenox 3

Speaker: – Brigham and Women's Hospital, Harvard Medical School

11:07 - 11:17 GMT

Sarcomatoid and Rhadoid De-Differentiation in Renal Cell Carcinoma and Clinical Implications

Location: Lenox 3

Speaker: – Mayo Clinic

11:17 - 11:30 GMT

Session 2 Q&A

Location: Lenox 3

Moderator: – The Francis Crick Institute/ The Royal Marsden Hospital

Moderator: – Brigham and Women's Hospital, Harvard Medical School

11:30 - 11:45 GMT

KEYNOTE I: Scotland and Kidney Cancer

Location: Lenox 3

Speaker: – University of Glasgow

CME Session

CME Credits: 0.25 CE credits

11:45 - 12:45 GMT

SESSION 3: CARING FOR THE WHOLE PATIENT: NON CLINICAL CONSIDERATIONS

Location: Lenox 3

Moderator: – Ludwig-Maximilians University of Munich

Moderator: – Vall d'Hebron University Hospital

CME Session

CME Credits: 1 CE credits

11:46 - 11:47 GMT

Introduction to Session 3

Location: Lenox 3

Speaker: – Ludwig-Maximilians University of Munich

11:47 - 11:57 GMT

Living with RCC - long term survival and frustration

Location: Lenox 3

Speaker: – Research and Innovation Unit of Radiology

11:57 - 12:07 GMT

Supplements and Concomitant Drugs - Interactions, Efficacy

Location: Lenox 3

Speaker: – Klinik Ottakring

12:07 - 12:17 GMT

Patients trust in care

Location: Lenox 3

Speaker: – KCCure

12:17 - 12:27 GMT

Quality of life - what is that and how can we optimize it?

Location: Lenox 3

Speaker: – Northwestern University/Feinberg School of Medicine

12:27 - 12:37 GMT

Rare subtypes - a patients tale

Location: Lenox 3

Speaker: – -

12:37 - 12:45 GMT

Session 3: Panel discussion & Q&A

Location: Lenox 3

Moderator: – Ludwig-Maximilians University of Munich

Moderator: – Vall d'Hebron University Hospital

12:45 - 14:15 GMT

POSTERS AND LUNCH

Location: Lenox 1

Poster SessionNetworking

14:16 - 14:17 GMT

Introduction to Session 4

Speaker: – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University

14:15 - 15:15 GMT

SESSION 4: ORAL ABSTRACTS

Location: Lenox 3

Moderator: – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University

Moderator: – University of Southern Denmark

Oral Abstract

CME Credits: 1 CE credits

14:17 - 14:27 GMT

Oral Abstract: Cross-trial propensity score weighted analysis of nivolumab plus ipilimumab versus nivolumab monotherapy for patients with untreated advanced renal cell carcinoma

Location: Lenox 3

Lead Author: – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)

14:27 - 14:37 GMT

Oral Abstract: Health Related Quality of Life (HR-QOL) Measures in Renal Cell Carcinoma: Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30 and EQ-5D.

Location: Lenox 3

Lead Author: – City of Hope Comprehensive Cancer Center

Quality of Care and Quality Improvement

14:37 - 14:47 GMT

Oral Abstract: Patients’ experiences on the course of treatment after partial nephrectomy or percutaneous cryoablation of small renal cell carcinoma - a cross-sectional multicenter study

Location: Lenox 3

Lead Author: – Research and Innovation Unit of Radiology

Patient-reported Outcomes

14:47 - 14:57 GMT

Oral Abstract: Eosinophilic solid and cystic renal cell carcinoma : a rare new entity associated with TSC1/TSC2 genetic alteration and rare metastatic potential.

Location: Lenox 3

Lead Author: – APHP-Centre, Université de Paris-Cité, INSERM UMR970

Tumor Biology, Biomarkers, and Pathology

14:57 - 15:07 GMT

Oral Abstract: Baseline circulating soluble factors as predictors of benefit from nivolumab in metastatic renal cell carcinoma (mRCC): additional multivariate analyses of the pooled translational NIVOREN GETUG-AFU26 population

Location: Lenox 3

Lead Author: – Institute Gustave Roussy /CHU St Pierre-CHU Brugmann

Tumor Biology, Biomarkers, and Pathology

15:07 - 15:15 GMT

Session 4 Q&A

Location: Lenox 3

Moderator: – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University

Moderator: – University of Southern Denmark

15:15 - 15:25 GMT

BREAK

Location: Lenox 1

15:25 - 16:30 GMT

SESSION 5: FIRST-LINE THERAPY DEBATES

Location: Lenox 3

Moderator: – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany

Moderator: – The Royal Marsden NHS Foundation Trust

CME Session

CME Credits: 1 CE credits

15:26 - 15:27 GMT

Introduction to Session 5

Location: Lenox 3

Speaker: – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany

15:27 - 15:37 GMT

Debate: In favour of IO-TKI Triplets

Location: Lenox 3

Speaker: – University of Texas Southwestern Medical Center

Speaker: – Institut Gustave Roussy

15:37 - 15:47 GMT

Debate: In favour of IO-TKI Doublets

Speaker: – Institut Gustave Roussy

15:47 - 15:57 GMT

Debate: In favour of IO-IO

Location: Lenox 3

Speaker: – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

15:57 - 16:07 GMT

Optimal toxicity management

Location: Lenox 3

Speaker: – Royal Marsden Hospital

16:07 - 16:17 GMT

Illustrative Clinical Scenarios

Location: Lenox 3

Speaker: – The Royal Marsden NHS Foundation Trust

16:17 - 16:30 GMT

Session 5: Panel discussion and Q&A

Location: Lenox 3

Moderator: – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany

Moderator: – The Royal Marsden NHS Foundation Trust

16:30 - 16:45 GMT

KEYNOTE II: John Fitzpatrick Award Lecture

Location: Lenox 3

Speaker: – HEGP, APHP, Université Paris-Centre

CME Session

CME Credits: 0.5 CE credits

16:45 - 17:00 GMT

Break

17:00 - 18:30 GMT

KCA RECEPTION

Location: Lenox 1

Networking

17:05 - 17:50 GMT

WOMEN IN RCC -SPONSORED BY EISAI

Location: Lenox 2

Moderator: – Institut Gustave Roussy

Moderator: – The Royal Marsden NHS Foundation Trust

Networking

18:00 - 18:30 GMT

Poster Walk

Location: Lenox 1

Moderator: – Medical Oncology Department. Hospital Universitario Marques de Valdecilla

Moderator: – Guy's and St. Thomas' NHS Foundation Trust

18:30 - 20:30 GMT

Optional Activities - Explore Edinburgh - Friday Evening

Networking

18:31 - 20:15 GMT

Tour #1 - Journey of Flavour - Johnnie Walker

Networking

18:31 - 20:30 GMT

Tour #2 Mercat Tours: Historic Underground Tour - SOLD OUT

Networking

08:30 - 09:00 GMT

WELCOME SESSION AND SESSION 6: KCA UPDATES

Location: Lenox 3

Moderator: – Duke University Medical Center

Moderator: – Klinik Ottakring

CME Session

CME Credits: 0.5 CE credits

08:31 - 08:40 GMT

KCA Updates

Location: Lenox 3

Speaker: – Institut Gustave Roussy

08:45 - 09:00 GMT

KEYNOTE III: Christopher G. Wood Rising Star Award Lecture

Location: Lenox 3

Speaker: – University of Washington

09:00 - 10:00 GMT

SESSION 7: BEYOND FIRST-LINE THERAPY

Location: Lenox 3

Moderator: – Institut Gustave Roussy

Moderator: – Duke University Medical Center

CME Session

CME Credits: 1 CE credits

09:01 - 09:02 GMT

Introduction to Session 7

Location: Lenox 3

Speaker: – Institut Gustave Roussy

09:02 - 09:12 GMT

Beyond first-line therapy: Selecting further lines of therapies after IO-IO

Location: Lenox 3

Speaker: – University of Michigan

09:12 - 09:22 GMT

Beyond first-line therapy: Selecting further lines of therapies after IO-TKI

Location: Lenox 3

Speaker: – Medical Oncology Department. Hospital Universitario Marques de Valdecilla

09:22 - 09:32 GMT

Integrating predictive biomarkers into therapy selection

Location: Lenox 3

Speaker: – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University

09:32 - 09:42 GMT

Optimizing later line therapy selection

Location: Lenox 3

Speaker: – University of Bari "A. Moro"

09:42 - 10:00 GMT

Session 7 Q&A

Location: Lenox 3

Moderator: – Duke University Medical Center

Moderator: – Institut Gustave Roussy

10:00 - 11:00 GMT

SESSION 8 - MANAGEMENT OF RCC

Location: Lenox 3

Moderator: – Centre Leon Bérard, Lyon I University

Moderator: – University of Michigan

CME Session

CME Credits: 1 CE credits

10:01 - 10:02 GMT

Introduction to Session 8

Location: Lenox 3

Speaker: – Centre Leon Bérard, Lyon I University

10:02 - 10:14 GMT

Future radiotherapy options

Location: Lenox 3

Speaker: – UTSW

10:14 - 10:26 GMT

Developments in Radiation Therapy in RCC

Location: Lenox 3

Speaker: – Istituto Europeo di Oncologia

10:26 - 10:38 GMT

Prognostication in RCC

Location: Lenox 3

Speaker: – Tom Baker Cancer Centr

10:38 - 10:50 GMT

Diagnostic and Therapeutic Imaging in RCC

Location: Lenox 3

Speaker: – Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany

10:50 - 11:00 GMT

Session 8 Q&A

Location: Lenox 3

Moderator: – Centre Leon Bérard, Lyon I University

Moderator: – University of Michigan

11:00 - 11:10 GMT

BREAK

Location: Lenox 1

11:10 - 12:10 GMT

SESSION 9: PROGRESS IN THE TREATMENT OF VARIANT HISTOLOGY RCC

Location: Lenox 3

Moderator: – Vall d'Hebron University Hospital

Moderator: – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

CME Session

CME Credits: 1 CE credits

11:11 - 11:12 GMT

Introduction to Session 9

Location: Lenox 3

Moderator: – Vall d'Hebron University Hospital

11:12 - 11:24 GMT

Papillary RCC

Location: Lenox 3

Speaker: – Medical University of Vienna, Austria

11:24 - 11:36 GMT

Chromophobe RCC

Location: Lenox 3

Speaker: – Georges Pompidou Hospital

11:36 - 11:48 GMT

Collecting Duct and Renal Medullary Carcinoma

Location: Lenox 3

Speaker: – Fondazione IRCCS Istituto Nazionale Tumori

11:49 - 12:00 GMT

HLRCC and Translocation RCC

Speaker: – University of Texas MD Anderson Cancer Center

12:00 - 12:10 GMT

Session 9 Q&A

Location: Lenox 3

Moderator: – Vall d'Hebron University Hospital

Moderator: – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

12:10 - 12:25 GMT

Break

12:10 - 13:40 GMT

POSTERS AND LUNCH

Location: Lenox 1

Poster SessionNetworking

12:30 - 13:30 GMT

Industry Session - MSD - Recent advances in the management of Renal cell Carcinoma

Location: Lammermuir 1&2

Speaker: – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany

Speaker: – Barts Cancer Institute

Non-CME Industry Sponsored Session

13:25 - 13:40 GMT

Break

13:40 - 14:40 GMT

SESSION 10: BASIC SCIENCE INTEGRATED INTO THERAPEUTIC MANAGEMENT

Location: Lenox 3

Moderator: – Charité - University Hospital

Moderator: – Brigham and Women's Hospital, Harvard Medical School

CME Session

CME Credits: 1 CE credits

13:41 - 13:42 GMT

Introduction to Session 10

Location: Lenox 3

Moderator: – Charité - University Hospital

13:42 - 13:52 GMT

TLS and B-cell responses in RCC

Location: Lenox 3

*Speaker:

13:52 - 14:02 GMT

Circulating T cell activation as predictor of therapy response

Location: Lenox 3

Speaker: – Emory University

14:02 - 14:12 GMT

Patient-derived organotypic cultures predict immunotherapy responses

Location: Lenox 3

Speaker: – Institute of Pathology, University Hospital Bonn

14:12 - 14:22 GMT

Transcriptomic heterogeneity in RCC

Location: Lenox 3

Speaker: – Charité - University Hospital

14:22 - 14:32 GMT

Optimizing clinical trial designs by integrating tissue derived markers

Location: Lenox 3

Speaker: – Hôpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, France

14:32 - 14:40 GMT

Session 10 Q&A

Location: Lenox 3

Moderator: – Charité - University Hospital

Moderator: – Brigham and Women's Hospital, Harvard Medical School

14:40 - 15:35 GMT

SESSION 11: SPECIAL TOPICS

Location: Lenox 3

Moderator: – Centre Leon Bérard, Lyon I University

Moderator: – University of Texas MD Anderson Cancer Center

CME Session

CME Credits: 1 CE credits

14:41 - 14:42 GMT

Introduction to Session 11

Location: Lenox 3

Moderator: – Centre Leon Bérard, Lyon I University

14:42 - 14:52 GMT

Modulating gut microbiome to influence outcomes with IO

Location: Lenox 3

Speaker: – Yale New Haven Hospital

14:52 - 15:02 GMT

HIF2a in VHL and beyond

Location: Lenox 3

Speaker: – University of Texas Southwestern Medical Center

15:02 - 15:12 GMT

Novel therapeutics *except HiF2a

Location: Lenox 3

Speaker: – Barts Cancer Institute

15:12 - 15:22 GMT

Therapy of patients with and of brain metastases

Location: Lenox 3

Speaker: – Centre Leon Bérard, Lyon I University

15:22 - 15:35 GMT

Session 11 Q&A

Location: Lenox 3

Moderator: – Centre Leon Bérard, Lyon I University

Moderator: – University of Texas MD Anderson Cancer Center

15:35 - 15:45 GMT

POSTER AWARD PRESENTATION

Location: Lenox 3

Moderator: – The Royal Marsden NHS Foundation Trust

Moderator: – University of Southern Denmark

CME SessionNetworking

CME Credits: 0.25 CE credits

15:45 - 16:50 GMT

WOODFIRE

Location: Lenox 3

Moderator: – Ludwig-Maximilians University of Munich

CME Session

CME Credits: 1 CE credits

15:46 - 15:47 GMT

Introduction to WoodFire Session

Location: Lenox 3

Speaker: – Ludwig-Maximilians University of Munich

15:47 - 15:59 GMT

Woodfire Panelist #1

Location: Lenox 3

Panelist: – Mayo Clinic

15:59 - 16:11 GMT

Woodfire Panelist #2

Location: Lenox 3

Panelist: – Barts Cancer Institute

16:11 - 16:23 GMT

Woodfire Panelist #3

Location: Lenox 3

Panelist: – University of Michigan

16:23 - 16:35 GMT

Woodfire Panelist #4

Location: Lenox 3

Panelist: – HEGP, APHP, Université Paris-Centre

16:35 - 16:50 GMT

Woodfire Q&A

Location: Lenox 3

Moderator: – Ludwig-Maximilians University of Munich

16:50 - 17:00 GMT

SESSION CLOSING

Location: Lenox 3

Moderator: – Ludwig-Maximilians University of Munich

Moderator: – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University

CME Session

CME Credits: 0.25 CE credits

17:30 - 19:15 GMT

Optional Activities - Explore Edinburgh - Saturday Evening

Networking

17:31 - 19:00 GMT

Tour #3 Holyrood Whiskey Tour and Tasting

Networking

17:31 - 19:15 GMT

Tour #4 Mercat Tours: Ghostly Underground Tour

Networking